RecruitingAttention-Deficit/Hyperactivity Disorder
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Eligible age
4–5.8 yrs
Accepts
All genders
Locations
24 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Sponsor: Supernus Pharmaceuticals, Inc.
You may qualify if…
- ✓ 1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
- ✓ 2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
- ✓ 3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
- ✓ 4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
- ✓ 5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
- ✓ 6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
- ✓ 7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
- ✓ 8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 \[Screening\] and continues with a similar duration/frequency throughout their study).
You may not qualify if…
- ✕ 1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
- ✕ 2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
- ✕ 3. History of Bipolar Disorder diagnosed in a first degree relative.
- ✕ 4. Has global development delay or intellectual disability by medical history.
- ✕ 5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
- ✕ 6. Has body mass index \> 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
- ✕ 7. Has a mean resting systolic and diastolic blood pressure\* that are both \>95th percentile for age sex, and height and has a mean resting pulse rate\* that is \>95th percentile for age and sex (males: \>117 bpm; females: \>122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). \* Note: The mean of three measurements while seated.
- ✕ 8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
Where it's recruiting
Alabama
Saraland
Arkansas
Fayetteville · Little Rock
California
Anaheim · Encino · Garden Grove · Imperial …
Colorado
Centennial
Florida
Clermont · Coral Gables · Gainesville · Jacksonville …
Georgia
Atlanta · Decatur · Savannah
Indiana
Evansville
Kentucky
Bardstown · Owensboro
Louisiana
New Orleans · Prairieville
Maryland
Baltimore
Massachusetts
Boston
Michigan
Bloomfield Hills
Source: ClinicalTrials.gov · NCT04781140 · last updated 2026-10-05